As part of our series focussing on medicines available in Australia, we have added a product review titled; Cemiplimab: an effective first-line therapy for advanced non-small cell lung cancer.
This review discusses indications and dosage, contraindications and a series of clinical studies featuring cemiplimab. It also provides commentary and guidance from Professor Nick Pavlakis.
Please login below to download this issue (PDF)